{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"582"},{"groupId":"OG001","value":"594"}],"units":"Participants"}],"title":"Contralateral invasive breast cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"582"},{"groupId":"OG001","value":"594"}],"units":"Participants"}],"title":"Contralateral non-invasive breast cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"734"},{"groupId":"OG001","value":"745"}],"units":"Participants"}],"title":"New primary ovarian cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"755"},{"groupId":"OG001","value":"756"}],"units":"Participants"}],"title":"New primary fallopian tube cancer"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"919"},{"groupId":"OG001","value":"911"}],"units":"Participants"}],"title":"New primary peritoneal cancer"}],"denoms":[{"counts":[{"groupId":"OG000","value":"921"},{"groupId":"OG001","value":"915"}],"units":"Participants"}],"description":"Number of patients with contralateral invasive breast cancer, contralateral non-invasive breast cancer, new primary ovarian cancer, new primary fallopian tube cancer and new primary peritoneal cancer. Analysis of contralateral breast cancers exclude patients with a bilateral mastectomy prior to randomisation. Analysis of new primary ovarian cancers excludes male patients and patients with a bilateral oophorectomy prior to randomisation. Analysis of new primary fallopian tube cancer excludes male patients and patients with a bilateral salpingectomy prior to randomisation. Analysis of new primary peritoneal cancers excludes male patients.","groups":[{"description":"Olaparib tablets 300mg taken orally twice daily.","id":"OG000","title":"Olaparib"},{"description":"Placebo tablets taken orally twice daily.","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS)","reportingStatus":"POSTED","timeFrame":"From date of randomisation to data cut off: 05 June 2024 (approximately 10 years 2 months)","title":"Number of Participants With Contralateral Invasive and Non-invasive Breast Cancer, New Primary Ovarian Cancer, New Primary Fallopian Tube Cancer and New Primary Peritoneal Cancer","type":"SECONDARY","unitOfMeasure":"Participants"}